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Abstract
Background: CASTLE compared the efficacy of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with
tenofovir-emtricitabine in ARV-naı ¨ve subjects from 5 continents.
Objectives: Determine the baseline rate and clinical significance of TDR mutations using ultra-deep sequencing (UDS) in
ARV-naı ¨ve subjects in CASTLE.
Methods: A case control study was performed on baseline samples for all 53 subjects with virologic failures (VF) at Week 48
and 95 subjects with virologic successes (VS) randomly selected and matched by CD4 count and viral load. UDS was
performed using 454 Life Sciences/Roche technology.
Results: Of 148 samples, 141 had successful UDS (86 subtype B, 55 non-B subtypes). Overall, 30.5% of subjects had a TDR
mutation at baseline; 15.6% only had TDR(s) at ,20% of the viral population. There was no difference in the rate of TDRs by
B (30.2%) or non-B subtypes (30.9%). VF (51) and VS (90) had similar rates of any TDRs (25.5% vs. 33.3%), NNRTI TDRs (11.1%
vs.11.8%) and NRTI TDRs (24.4% vs. 25.5%). Of 9 (6.4%) subjects with M184V/I (7 at ,20% levels), 6 experienced VF. 16
(11.3%) subjects had multiple TAMs, and 7 experienced VF. 3 (2.1%) subjects had both multiple TAMs+M184V, and all
experienced VF. Of 14 (9.9%) subjects with PI TDRs (11 at ,20% levels): only 1 experienced virologic failure. The majority of
PI TDRs were found in isolation (e.g. 46I) at ,20% levels, and had low resistance algorithm scores.
Conclusion: Among a representative sample of ARV-naı ¨ve subjects in CASTLE, TDR mutations were common (30.5%); B and
non-B subtypes had similar rates of TDRs. Subjects with multiple PI TDRs were infrequent. Overall, TDRs did not affect
virologic response for subjects on a boosted PI by week 48; however, a small subset of subjects with extensive NRTI
backbone TDR patterns experienced virologic failure.
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Introduction
Low abundance drug resistant HIV variants at levels as low as
1% of the circulating viral quasispecies can be detected in
antiretroviral (ARV)-naı ¨ve individuals by sensitive and quantita-
tive genotyping technologies [1–6]. These low abundance drug
resistant variants have been shown to potentially impact clinical
responses in individuals initiating non-nucleoside reverse tran-
scriptase based ARV therapy [7–14]. However, other studies did
not find a strong association with clinical responses [15–16]. The
conflicting results may have been the result of both the different
sensitive genotyping methods used in the investigations and the
disparate study populations that received heterogeneous antiret-
roviral regimens. Few studies have been able to control for the
antiretroviral regimens used when investigating the impact of low
abundance resistant variants on clinical outcomes.
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e10952Although low abundance resistant variants have been shown to
be important in some HIV-infected populations, there are only
limited data available on the rate of low abundance transmitted
drug resistance (TDRs) mutations in diverse ARV-naı ¨ve popula-
tions infected with B and non-B HIV subtypes [17]. There are also
little data on the clinical significance of low abundance variants
possessing TDRs in subjects who begin therapy with ritonavir-
boosted protease inhibitor (PI)-based therapy. An important
question in the HIV field currently is how persons who harbor
low abundance ARV-resistant variants respond to different ARV
treatment regimens.
The CASTLE study was a randomized open label study for
treatment naı ¨ve persons that compared the efficacy of atazanavir/
ritonavir (ATV/r) with lopinavir/ritonavir (LPV/r), each in
combination with tenofovir-emtricitabine (TDF/FTC) in ARV-
naı ¨ve subjects from 5 continents [18]. The previously reported
results demonstrated that ATV/r was non-inferior to LPV/r at
Weeks 48 and 96 [18–19]. Both regimens achieved consistent
response rates regardless of HIV subtype or number of baseline
protease gene polymorphisms present [18–19]. In addition, both
regimens had similar low rates of selection of new ARV resistance
mutations [18–21].
In this study, we report the baseline rate of low abundance drug
resistant HIV variants detected by ultra-deep sequencing in
persons infected with B and non-B subtypes from 5 continents
(Africa, Asia, Europe, North and South America). The association
of baseline drug resistant variants detected by ultra-deep
sequencing on virologic responses at Week 48 in the CASTLE
study is explored.
Results
Baseline Characteristics and Rate of TDRs
A total of 148 samples were recovered from the CASTLE study
sample archives for UDS. All 53 VF specimens and 95 VS
specimens were sequenced. The baseline characteristics of these
148 did not differ from the parent study population: mean age 35
years, 34% female, median CD4 cell count 191 cells/mm
3.
Baseline viral loads ranged from 3030 to .750,000 copies/mL
with a median viral load of 132,500 copies/mL.
Of the 148 baseline samples, 90 were subtype B, and 58 were
non-B subtype (A, AE, C, BF and F1). UDS results were obtained
on 141 of the samples (51 VF and 90 VS, 86 B and 55 non-B
subtypes) (Figure 1). Seven samples could not undergo UDS but
were genotyped by standard genotyping; 3 were non-B (AE)
subtype, and 4 were B subtype. One sample had UDS but no
standard genotype. Samples without UDS data had 1) only partial
UDS data obtained, 2) low viral loads, and/or 3) had undergone
prior freeze-thaw cycles for other analyses (Figure 1).
Overall, for subjects with UDS results, 30.5% had a TDR
mutation at baseline detected by UDS, and 15.6% had only
TDR(s) at ,20% rate in the viral population (Table 1). There was
no difference in the rate of TDRs by B (30.2%, 26/86) or non-B
subtypes (30.9%,17/55). At least one TDR was identified in a
sample from subtypes B, AE, C, and BF. There were only one
subtype A and one subtype F1 sample, neither with a TDR.
Samples from all 5 continents had TDRs by UDS: Africa 8/28
(28.6%), Asia 2/8 (25%), Europe 2/11 (18.2%), North America 8/
19 (42.1%), and South America 23/75 (30.7%). The overall rate of
any TDR by standard genotyping was 18/147 (12.2%) (Table 2).
There is no difference between VFs (6/52) and VSs (12/95)
regarding the rate of TDRs by standard sequencing, P=NS. UDS
detected more TDRs overall and by specific ARV class than
standard genotyping.
Specific TDR Antiretroviral (ARV) Mutation Class
Of the 141 subjects with a UDS result, 35 (24.8%) had a
nucleoside(tide) reverse transcriptase inhibitor N(t)RTI(s) TDR; 26
of these had a thymidine analog mutation (TAM) [22], 9 had a
M184V/I, and 2 had a variant with a K65R. Sixteen subjects
(11.3%) had non-nucleoside reverse transcriptase inhibitor
(NNRTI) TDR; of these, 15 had one or more of K103N,
Y181C/I or G190A/E. Fourteen subjects (9.9%) had a protease
inhibitor (PI) TDR. Eighteen subjects (12.8%) had TDRs from at
least two different ARV classes.
Figure 1. Results of Ultra Deep Sequencing Analysis. 148 samples recovered and sent for UDS: Subtype B (n=90), Non-B (n=58); 53 were VF
and 95 were VS. 141 samples had UDS data: Subtype B (n=86), Non-B (n=55) 51 VF and 90 VS. Of the 7 samples without UDS data, 2 had partial UDS
data and were not included; 3 samples were exhausted; and 2 had low viral loads and unable to amplify. VF: Virologic Failure, VS: Virologic Success.
doi:10.1371/journal.pone.0010952.g001
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a ,20% levels. The majority of PI TDRs (10/14) were present as
solitary PI TDRs (e.g. 24I, 32I, 46I or 58E). Only 4 subjects had
.1 PI TDRs: 3 clade B samples with 85V+90M; 46I+84V; and
46I+ 58E+84V+85V+90M; and one clade C sample with 32I+46I.
The PI TDR patterns were interpreted for all subjects with the
Stanford HIVdb algorithm [23]. Only one subject had high level
resistance to the PI used (ATV), possessing TDRs 46I, 58E, 84V,
85V, and 90M.
Association of TDRs with Virologic Success (VS) and
Virologic Failure (VF)
Among the 141 samples with a UDS result, there was no
difference in the rates of TDRs among those with VS 33.3% (30/
90) and VF 25.5% (13/51) by Week 48 (P=0.35). Rates of TDRs
by ARV class in those with VF and VS are shown in Figure 2.
Although the VS group had more PI TDRs by UDS than the VF
subjects (14.4% vs. 2.0%, P=0.02) most PI TDRs were found in
isolation, had low Stanford HIVdb scores [23] (e.g. 24I, 32I, 46I,
and 58E), and were at ,20% of the viral population. One patient
had multiple PI and N(t)RTI TDRs in high abundance (.20%)
and experienced virologic failure.
Specific TDRs known to affect the N(t)RTI backbone
Considering specific TDRs that could impact virologic response
to the N(t)RTI backbone, TDF/FTC, used in the study, 9 (6.4%)
of the subjects had M184V/I identified by UDS at baseline. Seven
of 9 M184V/I were at ,20% levels and were not detected by
standard genotyping. Six of the 9 experienced VF; 4 of these also
had TAMs, and 1 had K65R+TAMs (Table 3). Specific TDR
patterns and levels for subjects with a M184V/I and K65R are
shown in Table 4. Sixteen subjects (11.3%) had multiple TAMs by
UDS and 7 experienced VF. Three (2.1%) subjects had M184V
and multiple TAMs, and all were VF; 2 subjects had a K65R at
baseline by UDS (1 VF and 1 VS) (Table 3).
Discussion
Among a representative sample of ARV-naı ¨ve subjects from the
CASTLE study, HIV variants possessing TDR mutations were
commonly detected by UDS. Similar rates of TDRs were
identified in B and non-B subtypes. Although the study was not
designed to evaluate TDRs by continent nor specific subtype, at
least one sample from ARV-naı ¨ve subjects from 5 continents
(Africa, Asia, Europe, North and South America) had a TDR by
UDS. These data suggest that among subjects entering large
international clinical trials, TDRs are common in ARV-naive
persons from diverse populations and infected with B and non B
subtypes. Many of these subjects harboring HIV variants with
TDRs were not detected by standard genotyping. The overall
Table 1. Prevalence of low and high abundance Transmitted Drug Resistance Mutations (TDRs) by antiretroviral drug class.
WHO TDR Mutation Class ,20% of viral Population
1 $20% of viral Population
2 Subjects with any TDR
Any TDR 22 (15.6%) 21 (14.9%) 43 (30.5%)
N(t)RTI 19 (13.5%) 16 (11.3%) 35 (24.8%)
NNRTI 12 (8.5%) 4 (2.8%) 16 (11.3%)
PI 11 (7.8%) 3 (2.1%) 14 (9.9%)
N(t)RTI(s)- nucleoside(tide) reverse transcriptase inhibitor; NNRTI – non-nucleoside reverse transcriptase inhibitor, PI – protease inhibitor. Samples with multiple TDRs
present with at least one TDR representing $20% of the viral populations were scored as having $20% of the viral population (e.g. M184V at 5% and a T215Y at .20%
are in the $20% column). Only samples where all TDRs were at ,20% levels are represented in the ,20% column; 21 subjects had at least 1 TDR at high level $20%: 6
VFs and 15 VSs. There was no difference between VFs (6/51) and VSs (15/90) regarding the rate of high level ($20%) TDRs. P-value=0.47 Fisher’s exact test.
1Only TDRs occurring at ,20% of the viral population.
2At least 1 TDR occurring at $20% of the viral population.
doi:10.1371/journal.pone.0010952.t001
Table 2. Prevalence of transmitted drug resistance (TDR)
mutations by Ultra-deep Sequencing (UDS) and by standard
genotyping (SG).
WHO TDR ARV class
% of Subjects with a
TDR by UDS (n=141)
% of Subjects with a
TDR by SG (n=147)
Any TDR 30.5% 12.2%
N(t)RTI 24.8% 9.5%
NNRTI 11.3% 2.0%
PI 9.9% 2.0%
N(t)RTI – nucleoside(tide) reverse transcriptase inhibitor; NNRTI – non-
nucleoside reverse transcriptase inhibitor, PI – protease inhibitor. 141 subjects
with UDS data; 147 subjects with standard genotypic data.
doi:10.1371/journal.pone.0010952.t002
Figure 2. Transmitted Drug Resistance by ARV Class and
Virologic Outcome. Transmitted Drug Resistance by ARV Class and
Virologic Outcome: Note: TDRs are not mutually exclusive (i.e. a subject
could have a TDR from more than one ARV class). VS: Virologic Success,
VF: Virologic Failure N(t)RTI(s)- nucleoside(tide) reverse transcriptase
inhibitor; NNRTI – non-nucleoside reverse transcriptase inhibitor, PI –
protease inhibitor. Any: Any transmitted drug resistance mutations.
Any TDR: p-value=0.35, NRTI: p-value=1, NNRTI: p-value=1, PI:
p-value=0.02.
doi:10.1371/journal.pone.0010952.g002
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study is similar to other investigations that reported rates between
28 to 33% depending on the populations studied and the sensitive
genotyping methods used to identify low abundance resistant
variants [14–16,24].
When considering TDRs both overall and by specific ARV
class, TDRs were not associated with a lower virologic response for
subjects initiating a boosted PI-based regimen. However, a small
subset of subjects with specific N(t)RTI TDR patterns that could
impact the activity of the TDF/FTC backbone used in the study
did experience a higher rate of virologic failure. Interestingly,
subjects with a PI TDRs identified by UDS at baseline did well on
a boosted PI regimen. Possible reasons for this apparently non-
intuitive finding include: 1) most PI TDRs were found in isolation
(few subjects had multiple PI TDRs), 2) the PI TDRs identified
had low Stanford HIVdb scores [23] (e.g. 24I, 32I, 46I, and 58E
and some of these have been previously described to be naturally
occurring polymorphisms within the HIV-1 protease gene [2], and
3) the majority of PI TDRs were at very low levels of the viral
population (,20% of the population). Thus, PI TDRs identified
by UDS may have little impact on virologic response when the
TDR is found in isolation and at low levels, especially in a person
initiating a boosted PI regimen with a high genetic barrier to
resistance. The PI TDR patterns were interpreted for all subjects
with the Stanford HIVdb algorithm [23]. Only one subject had
high-level resistance to the PI used (ATV). This subject
experienced VF and had multiple PI TDRs (46I, 58E, 84V,
85V, 90M) in high abundance (.20% levels). This subject
demonstrates the previously known information that multiple PI
TDRs present at high levels can impact virologic responses to
boosted PI based regimens [18–21,25–29].
There was no difference in the rate of NNRTI TDRs in subjects
with VS or VF with approximately 11% having a TDR NNRTI
Table 3. Virologic outcome at Week 48 and specific TDR at
Baseline known to affect NRTI Backbone.
Specific TDR
Mutations
VS
(n=90)
VF
(n=51)
Total # of Subjects with
Specific TDR (n= =141)
M184V/I +/2
TAMs +/2 K65R
369
.1 TAMs 9 7 16
K65R 1 1 2
Thymidine Analog Mutations (TAMs); Virologic Success at week 48 (VS),
Virologic Failure at week 48 (VF). Transmitted Drug Resistance Mutations (TDRs);
9 subjects with M184V/I +/2 TAMs and/or +/2 K65R at baseline. 16 subjects
with .1 TAMs at baseline. 2 subjects with K65R at baseline.
doi:10.1371/journal.pone.0010952.t003
Table 4. Specific TDR patterns and levels for subjects with a M184V/I and/or K65R +/2 TAMs.
ID Clade 48 w VL TAMs TDRs at baseline with UDS
1 - ATV B VF 334,000 1 RT: M184V(1%), T215F(1%), G190A(0.9%)
PR: I13V(1.5%), L63P(99.1%), A71T(96.9%)
2 - ATV B VS 545,000 RT: D67G(1.3%), M184V(0.9%), K103N(67.6%)
PR: L10F(1.6%), L10I(95.4%), I13V(1.3%), K20V(1.3%),V32I(1.4%),
M36I(3.6%), L63P(0.9%), V82I(98.6%), I93L(99.2%)
3 - ATV B VF 193,000 5 RT: M41L(1.72%), D67N(1.87%), K70R(1.67%), M184V(5.9%),
T215Y(20.49%), K219Q(26.99%)
PR: I13V(23.23%), K20R(1.42%), M36I(98.11%), I62V(99.18%),
L63P(100%), A71T(29.74%), I93L(96.64%)
4 - ATV B VS 168,000 RT: M184I(1.25%), V179D(26.85%)
PR: M36I(1.16%), M46I(1.08%), L63P(100%), V77I(6.49%),
I84V(1.11%)
5 - ATV B VF 158,000 2 RT: M41L(94.79%), M184V(96.76%), T215Y(97.69%)
PR: L10F(99.21%), M46I(20.87%), Q58E(91.85%), I62V(8.48%),
L63P(98.8%), I64V(2.26%), V77I(58.2%), I84V(36.63%), I85V(45.4%),
L90M(46.63%), I93L(91.49%)
6-LPV
# C VF 750,000 3 RT: K65R(3.11%), M184V(13.79%), L210W(9.27%),
T215Y(9.1%), K219Q(4.66%), G190A (4.57%)
PR: L10I(3.22%), L10I(77.13%), I13V(72.43%), M36I(82.5%), L63P(1.06%),
H69K(94.02%), I93L(45.59%)
7 - LPV B VF 35,000 RT: M184I(3.37%)
PR: I62V(98.93%), L63P(100%), I64L(100%), V82I(90.91%), I93L(94.44%)
8 -LPV B VF 37,000 RT: M184V(95.98%), K103N(14.24%)
PR: I64V3(99.82%)
9 - LPV C VS 38,100 1 RT: V75A(1.95%), M184V (1.43%), L210W(1.3%), K103R(2.98%)
PR: K20M(98.93%), M36I (97.89%), K43T(1.31%), I62V(100%) L63P(100%),
H69K(100%), I93L(99.76%)
10 - ATV BF VS 8840 6 NRTI: M41L(7.47%), K65R(7.85%), D67N(33.78%), K70R(6.34%),
Y118I(1.65%), L210W(16.74%), T215C(20.98%), K219N(22.46%)
NNRTI: K103N(16.36%), K103R(10.27%), V179D(73.28%), Y181C(2.34%)
PI: L10R(2.51%), M36I(91.67%), M46I(3.3%), D60E(2.51%), L63P(3.28%),
I64L(2.88%), V77I(1.79%), V82I(92.67%), I93L(90.53%)
VF: Virologic Failure VS: Virologic Success NRTI: Nucleoside Reverse Transcriptase Inhibitor NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor PI: Protease Inhibitor.
TAMs: Thymidine Analogue Mutations. HIV VL: HIV Viral Load. TDRs: Transmitted Drug Resistance Mutations. 6-LPV
# has both a M184V and a K65R TDR. Bold: M184V,
TAMs, Major PI mutations according to HIV Stanford Database.
doi:10.1371/journal.pone.0010952.t004
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resistant variants, a boosted PI regimen may be successful at
suppressing the resistant variants. It has been previously shown
that many of the low abundance resistant variants identified by
UDS may not affect virologic outcomes if the resistant variants
identified are only resistant to ARVs that are not part of the
antiretroviral regimen being employed [14,30].
Although there was no difference in the rate of N(t)RTI TDRs
in those subjects with VS or VF, there were subjects with extensive
N(t)RTI TDR mutations which are known to impact responses to
TDF/FTC. There was a high rate of VF in the small number of
subjects with a M184V, even when the TDR was present at ,20%
levels of the quasispecies and missed by standard genotyping
methods. Subjects with multiple TAMs also had disproportionate
rates of VF. These results suggest that M184V and specific
patterns of N(t)RTI mutation patterns may contribute to
predicting response to a boosted PI regimen. However, the
number of subjects in this study is small, and more studies should
be done to investigate the impact of specific N(t)RTI TDR
patterns present in low abundance on virologic responses in
subjects initiating boosted PI regimens.
A strength of this study was that the patient population was
recently sampled (enrolled between 2005–2006), well character-
ized, and represented multiple diverse ARV-naı ¨ve groups and
HIV subtypes. A limitation of this study was that it was a
retrospective case control study with the inherent limitations of
such a design. The study design allowed us to explore the
association of TDRs with clinical responses with a boosted PI
regimen and the rate of TDRs in B and non B subtypes.
However, investigations into the prevalence of TDRs across
continents or patterns of specific TDRs by HIV subtype could
not be definitely defined given that the numbers in each category
were too few. Future studies should be performed to determine
the prevalence of TDRs by UDS in larger retrospective and
prospective studies.
Also, recent reports have suggested that the absolute number of
viral variants with a TDR mutation, or ‘‘mutational load,’’ may
impact the time to virologic failure in a person on therapy [31–33].
Although our study was not designed to specifically determine
mutational load association with virologic response, subjects with
high mutational loads were generally more likely to experience VF
(data not shown). Thus, several factors should be considered when
evaluating minor variants effect on treatment response, such as,
the specific TDR resistance conferring effect, the proportion of
variants possessing the mutation (mutational load), the total
number of TDRs present that affect the regimen and whether
these TDRs are linked on same viral genome, and the genetic
barrier of the specific ARV regimen being used. Virologic
outcome based on baseline minority variants is likely multifacto-
rial, and is not simply based on presence or absence of a mutation
or a simple mutation percentage, as some mutations and
mutational loads likely can be suppressed by specific regimens,
in this case a boosted PI regimen [31–33].
Further studies should be performed to determine how the viral
factors of mutational load, mutation linkage (mutations within the
same viral genome), and specific mutational patterns interact and
impact treatment responses to the many different antiretroviral
regimens now used in the clinic. These important virologic
parameters will need to be better defined, and the resistance
interpretation algorithms accordingly adapted before sensitive
genotyping technologies can be incorporated into routine HIV
clinical care.
In summary, among a representative sample of ARV-naı ¨ve
subjects in the CASTLE study, transmitted drug resistance
mutations identified by ultra-deep sequencing were common,
and B and non-B HIV-1 subtypes had a similar rate of TDRs.
TDRs identified by UDS did not affect virologic response for
subjects on a boosted PI. However, a small subset of subjects with
extensive N(t)RTI backbone TDR patterns were likely to
experience virologic failure. Further investigations should be
performed to determine the prevalence of TDRs in diverse
populations of HIV infected persons across the different regions of
the world. Studies should also be done to determine which ARV
regimens are best at suppressing HIV variants possessing TDRs at
different variant levels and mutation patterns.
Methods
Trial population and sample selection
The CASTLE study was a 96 week study comparing the
antiviral efficacy and safety of ATV/r with LPV/r, each in
combination with TDF/FTC in HIV-infected treatment-naı ¨ve
subjects. The primary objective of the study was to compare the
proportion of subjects with HIV RNA levels ,50 c/mL at Week
48 between the ATV/r+TDF/FTC and LPV/r+TDF/FTC
regimens. The primary analysis of the study confirmed the
hypothesis that ATV/r/TDF/FTC was non inferior to LPV/
r/TDF/FTC with 78% and 76% of subjects respectively,
having HIV RNA ,50 c/mL at Week 48. Subjects were enrolled
from 5 continents (Africa, Asia, Europe, North and South
America) representing 28 countries and had given informed
consent [18–19].
Based on prior studies [14,24,34], our research hypothesis was
that low frequency drug resistant HIV variants would be detected
in baseline samples in 10–20% of subjects with virologic failure. A
retrospective case control study was performed to determine the
baseline rate of low (,20% of the viral population) and high
abundance ($20%) drug resistant HIV variants by ultra-deep
sequencing in subjects with virologic failure (VF) and virologic
success (VS) defined by Confirmed Virologic Response (CVR) for
HIV RNA ,400 copies/mL by Week 48 [18–21]. Baseline
specimens were selected from all subjects with VF by week 48
(N=53: 27 from ATV/r arm and 26 from LPV/r) and from 95
VS subjects (n=50 from ATV/r arm and n=45 from LPV/r
arm). VS samples were randomly selected using stratified sampling
by baseline HIV RNA and CD4 so that the VS had similar
baseline HIV RNA and CD4 as the VF subjects.
Subjects were selected from all 5 continents, and 6 different
HIV subtypes were represented. Baseline demography, CD4 cell
count and viral load values, and baseline HIV genotype by
standard genotyping (Monogram Biosciences, CA) were obtained
from the clinical trial database.
Ultra-deep sequencing (UDS)
Coded baseline plasma samples were sent to Yale for ultra-deep
sequencing (UDS) using 454 Life Sciences sequencing center
(Branford, CT). The method for UDS has been described
elsewhere [14,34,35]. However, in brief, three gene-specific
overlapping cDNA per sample were generated from extracted
RNA and subjected to 40 cycles of PCR. These products were
then used to make eight partly overlapping amplicons covering the
HIV-1 pol gene (protease and reverse transcriptase gene codons 1–
236). The amplicons were purified with AMPure magnetic beads
(Agencourt, Beverly, MA) and quantitated by PicoGreen fluores-
cence (Invitrogen). After equimolar pooling of amplicons, clonal
amplification on beads was performed using UDS sequencing kits
(Roche/454 Life Sciences, Branford, CT). Sample emulsions were
pooled, enriched, and counted on a Multisizer3 Coulter counter.
UDS and HIV Drug Resistance
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Sequencing was performed on a Genome Sequencer FLX
(Roche/454 Life Sciences). An average of 1700 reads per
nucleotide position was obtained for this set of samples, which
allowed for accurate detection of variants down to approximately
1% when viral load is .10,000 copies/mL [14,34]. In this study
5.4% (8/148) of samples had viral loads ,10,000; 5 had successful
UDS (viral loads of 9680, 7030, 8840, 5870, and 9190 copies/mL)
with good sequencing depth coverage (ave. ,1500 reads) and were
included. Given stochastic effects of RNA sampling for samples
with VL,10,000 copies/mL, the proportion of variants in these
samples reflect the proportion of mutations within the PCR
amplicons sequenced and may or may not reflect the proportion in
plasma [14,34]. Amplicon Variant Analyzer software was used to
align all amplicon sequence reads to a consensus sequence. The
limit of detection for TDRs by UDS was restricted to $1% of the
viral population [14,34,35].
Standard genotypic resistance profiles
Standard genotypic resistance mutation results were determined
using Monogram Biosciences GeneSeq technology (South San
Francisco CA) [18–21].
Transmitted Drug Resistance Definition
The 2009 World Health Organization reference list of
transmitted drug resistance mutations (TDRs) was used to evaluate
for the rate of mutations detected by standard and ultra-deep
sequencing [17].
Statistical Methods
Proportions of subjects with TDRs detected by UDS were
presented overall and by HIV subtypes, regions, and outcomes at
Week 48 (VF or VS). Specific TDR mutation classes (NRTI,
NNRTI and PI) were presented similarly. The proportions of
subjects with TDRs (all mutations and by specific ARV class) at
,20% of the viral population were further calculated. Proportions
of subjects with TDRs by B vs. non-B subtypes were compared
using Fisher’s exact test [36]. Proportions of subjects with TDRs
(all mutations and by specific ARV class) by VF vs. VS at Week 48
were also compared using Fisher’s exact tests.
The parent CASTLE study is registered with ClinicalTrials.gov,
number NCT00272779.
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